Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II MRI-guided de-escalation of neoadjuvant pembrolizumab + paclitaxel + carboplatin in early triple-negative breast cancer
MOH_2025-09-30_014367Phase 2Not yet recruiting
- Sponsor
- ד"ר יעל בר (איכילוב), ד"ר טל סלע (שיבא)
- Start
- Aug 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, paclitaxel, carboplatin, doxorubicin and cyclophosphamide in triple-negative breast cancer (TNBC) and breast cancer, sponsored by ד"ר יעל בר (איכילוב), ד"ר טל סלע (שיבא). Primary endpoint: Pathologic complete response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on MOH_2025-09-30_014367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-30_014367.